Sagimet Biosciences reported third quarter 2026 financial results and provided a corporate update on its Phase 3 AURORA clinical trial for denifanstat in moderate to severe acne. The company highlighted a pro forma cash position of $356 million following a $115 million equity financing in October, which is expected to fund operations through mid-2029.
“Building on the positive Phase 3 results from our license partner Ascletis, we have initiated our pivotal U.S. AURORA Phase 3 clinical trial. With our October equity financing, we are well positioned to fund our programs through mid-2029, including the anticipated Phase 3 denifanstat data readout and the potential submission of an NDA.”
Sagimet Biosciences Inc. reported a significant increase in total assets to $282.1 million as of September 30, 2026, up from $116.5 million at the end of 2025, primarily driven by growth in cash and marketable securities. The company is advancing its lead drug candidate, denifanstat, through clinical trials for metabolic dysfunction-associated steatohepatitis (MASH) and other indications. Current liabilities also increased to $38.0 million, including a $27.5 million liability for proceeds received for equity not yet issued.
Sagimet Biosciences Inc. has updated its corporate investor presentation, which will be used by management in upcoming meetings with investors. The presentation, filed as Exhibit 99.1, provides an overview of the company's novel therapeutics targeting metabolic dysfunction, including its lead candidate denifanstat.